| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6182890 | Gynecologic Oncology | 2012 | 4 Pages |
Abstract
⺠We detected no difference in either progression free or overall survival between patients who required dose adjustments and treatment delays and those who did not. ⺠As seen in other cancers, the most common reasons for chemotherapy delays/reductions were neutropenia, thrombocytopenia, and neuropathy.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
C.I. Nagel, F.J. Backes, E.M. Hade, D.E. Cohn, E.L. Eisenhauer, D.M. O'Malley, J.M. Fowler, L.J. Copeland, R. Salani,